OrganiGram Holdings Inc. (ACB:CSE) has provided an update to shareholders while reviewing milestones of 2014 and looking at the growth and goals of 2015.
Since the inception of OrganiGram in April, 2014, the company has been growing and developing at a very fast pace. Through this growth, there have been some tremendous achievements, which include receiving its organic certification, producing its first crops, listing of shares on the TSX Venture Exchange and completing three phases of construction. OrganiGram is excited to capitalize on these achievements and execute on the business plan.
Moving forward, the company’s shareholders, patients and partners will begin to see the results from the foundation laid in 2014. To date, the company has been extremely focused on expanding the production facility while, at the same time, working to increase production levels. These efforts will begin to provide significant product to the market in March of this year. Thereafter, the utilization of the company’s existing rooms and rooms under construction will ensure that OrganiGram is poised to meet its financial goals in 2015.
OrganiGram would like to take this opportunity to congratulate Trauma Healing Centers on the opening of its first clinic, in Halifax, N.S. OrganiGram is proud to be partnered with Trauma Healing Centers on research initiatives to assist veterans and others suffering with posttraumatic stress disorder (PTSD).
OrganiGram’s chief executive officer, Denis Arsenault, states: “Over the past few months, OrganiGram has moved into a best-in-class manufacturing facility. Our processes and systems have been developed to a point where we produce high-quality products, in an organic form, which has and will continue to exceed the requirements of our clients. While we continue to evolve and improve, our facility will begin to supply the market with an established source of product on a consistent basis. We have a superior management team in place that is not only focused on supply but also quality, efficiency and product development. The results of our efforts will not only be very profitable for the company and shareholders but most importantly will provide a rapidly increasing client base with a medicinal product that assists in a much-improved quality of life for many. The developments of the next few weeks and months will be both exciting and fruitful for our company.”
We seek Safe Harbor.